Efficacy and main therapeutic effects of enantuzumab

Elranatamab is a bispecific T cell-linked antibody drug specifically used to treat multiple myeloma. Its design concept is based on precise activation of the immune system. As a new generation of immunotherapy drug, eractuzumab guides T cells to the surface of myeloma cells and achieves efficient and selective killing of malignant plasma cells through collaborative recognition, breaking the dilemma of poor therapeutic effects of traditional chemotherapy and monoclonal antibodies.

The biggest therapeutic highlight of this drug is that it combines two different targets: one end recognizes the specific protein on the surface of myeloma cellsBCMA (B cell maturation antigen), while the other end binds to the CD3 molecule on the surface of T cells. Through this "dual-target bridging" mechanism, Enactuzumab can accurately guideT cells to the vicinity of tumor cells, induce T cell activation and release cytotoxic substances, such as perforin and granzymes, thereby triggering rapid apoptosis of tumor cells.

In the treatment of patients with refractory or relapsed multiple myeloma, ernatumumab has obtained breakthrough drug designation from the FDA and EMA overseas and has shown durable response rates in multiple clinical studies. Compared with traditional chemotherapy, its side effects are relatively mild, and it does not require patients to be hospitalized for long periods of time, which greatly improves the quality of life and medication compliance. It is particularly suitable for patients who are resistant to other drugs such as lenalidomide, bortezomib or CD38 monoclonal antibodies.

In addition, ernatumumab shows a rapid response in the early stage of treatment, and the clinical manifestations of decreased M protein levels and shrinkage of bone marrow lesions can be seen within weeks after administration. Some patients even achieve sustained complete remission, demonstrating deep disease control. With the optimization of dosage forms and the development of combination therapies, this drug may also become one of the future candidates for maintenance treatment or even first-line treatment of multiple myeloma.

Reference materials:https://www.drugs.com/mtm/elranatamab.html